
Novavax, Inc. (NASDAQ:NVAX) shares are trading higher Thursday after Australia’s national drug regulator granted approval for the company's COVID-19 vaccine.
The stock is trading below what traders call a pennant pattern and is showing uncertainty in where it could head next.